Watts G F, Castelluccio C, Rice-Evans C, Taub N A, Baum H, Quinn P J
Department of Endocrinology and Chemical Pathology and Public Health Medicine (UMDS), St Thomas's Hospital, London.
J Clin Pathol. 1993 Nov;46(11):1055-7. doi: 10.1136/jcp.46.11.1055.
Plasma coenzyme Q (CoQ) was measured in 20 hyperlipidaemic patients treated with diet and simvastatin (an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase); 22 hyperlipidaemic patients treated with diet with alone; and 20 normal controls. Patients treated with simvastatin had a significantly lower plasma CoQ and CoQ: cholesterol ratio than either patients receiving diet alone or normal controls. Use of simvastatin was inversely and independently correlated with both CoQ (p < 0.0001) and CoQ: cholesterol ratio (p < 0.01). There was a significant inverse association between CoQ and dose of simvastatin (p < 0.001). It is concluded that simvastatin may lower the plasma CoQ concentration and this may be greater than the reduction in cholesterol. The possible adverse effect of simvastatin on the metabolism of CoQ may be clinically important and requires further study.
对20例接受饮食和辛伐他汀（3-羟基-3-甲基戊二酰辅酶A（HMG CoA）还原酶抑制剂）治疗的高脂血症患者、22例仅接受饮食治疗的高脂血症患者以及20例正常对照者测定了血浆辅酶Q（CoQ）。接受辛伐他汀治疗的患者血浆CoQ及CoQ与胆固醇比值显著低于仅接受饮食治疗的患者或正常对照者。辛伐他汀的使用与CoQ（p<0.0001）及CoQ与胆固醇比值（p<0.01）均呈负相关且独立相关。CoQ与辛伐他汀剂量之间存在显著负相关（p<0.001）。得出结论，辛伐他汀可能降低血浆CoQ浓度，且这种降低可能大于胆固醇的降低。辛伐他汀对CoQ代谢可能产生的不良影响在临床上可能很重要，需要进一步研究。
